FCA
CODX

FinTrust Capital Advisors’s Co-Diagnostics CODX Stock Holding History

FinTrust Capital Advisors’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-30
Closed -$12 – 1085
2020
Q3 		$12 Buy
+30
New +$15.4K ﹤0.01% 750

Other funds holding CODX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

FinTrust Capital Advisors's CODX Position: Q4 2020 in Review

FinTrust Capital Advisors sold out of Co-Diagnostics (CODX) in Q4 2020, closing a stake of 30 shares — an estimated $12 sold.

FinTrust Capital Advisors first reported a position in CODX in Q3 2020 and held it in 1 quarter. The position peaked at $12 in Q3 2020. 83 funds tracked by Wall St. Rank hold CODX as of Q4 2020.

  • FinTrust Capital Advisors reported no remaining Co-Diagnostics position as of Q4 2020 after selling out during the quarter.
  • FinTrust Capital Advisors sold 30 Co-Diagnostics shares in Q4 2020, an estimated $12.
  • FinTrust Capital Advisors first reported a position in Co-Diagnostics in Q3 2020 and held it in 1 quarter.
  • FinTrust Capital Advisors's Co-Diagnostics position peaked at $12 in Q3 2020.
  • 83 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2020.

Based on FinTrust Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.